← Oncology Approval Tracker

FDA DECISION ·

Lynozyfic

linvoseltamab-gcpt · Regeneron Pharmaceuticals

Accelerated approvalNew therapyMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with relapsed or refractory multiple myeloma after at least four prior lines, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.

LAMPGEN ANALYSIS

Why it matters

The BCMA×CD3 bispecific antibody expands late-line treatment options, with clinical benefit to be confirmed.

What research teams should watch

Verify required prior drug classes and plan inpatient observation for step-up doses under the labeled risk-management program.

PRIMARY RECORDS

Sources